Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
25 janv. 2022 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Lui Franciosi To Assess the Safety and Efficacy of a New Dementia Treatment
05 janv. 2022 16h00 HE
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that Franciosi Consulting Ltd. will be reviewing and monitoring the safety and efficacy of the new...
LiveFreely Announces Apple Watch Version of 'BUDDY,' the Predictive AI-Driven Digital Health Assistant for Seniors and Their Loved Ones
22 déc. 2021 09h00 HE
|
LiveFreely Inc
SAN JOSE, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- LiveFreely, Inc., a Silicon Valley digital health company that develops innovative technology to improve the health and well-being of seniors and...
ADM Diagnostics, Inc. Announces Launch of CorInsights® MRI
14 déc. 2021 10h00 HE
|
ADM Diagnostics Inc
NORTHBROOK, Ill., Dec. 14, 2021 (GLOBE NEWSWIRE) -- ADM Diagnostics, Inc. (ADMdx) has received FDA clearance for CorInsights MRI. Using a standard MRI scan, CorInsights MRI provides quantitative...
Improving Social Equity in Dementia Prevention and Care
30 nov. 2021 08h00 HE
|
Posit Science
WASHINGTON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Jeff Zimman, Co-Founder of Posit Science, which makes the brain training app BrainHQ, will address the annual What’s Next Longevity Innovation Summit in...
The Alzheimer’s disease market is anticipated to grow at an annualized rate of over 13%, till 2030, claims Roots Analysis
27 oct. 2021 07h45 HE
|
Roots Analysis
London, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Alzheimer's Disease Market (2nd Edition), 2021-2031” report to its list of offerings. Limited treatment...
Global Rheumatoid Arthritis Diagnosis Tests Market Report 2021: Market to Reach $766.7 Million by 2026 - Serology Segment to Account for $561.3 Million
08 oct. 2021 05h08 HE
|
Research and Markets
Dublin, Oct. 08, 2021 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Diagnosis Tests - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
TMS (Transcranial Magnetic Stimulator) Market ($2.02Bn by 2028) Growth Forecast at 8.8% CAGR During (2021-2028) - COVID-19 Impact and Global Analysis by TheInsightPartners.com
24 août 2021 15h44 HE
|
The Insight Partners
New York, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Transcranial Magnetic Stimulator (TMS) Market: Key InsightsAccording to our latest study on “Transcranial Magnetic Stimulator (TMS) Market Forecast to...
ANVS BREAKING ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Annovis Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ANVS
19 août 2021 18h15 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
10 août 2021 07h00 HE
|
BioXcel Therapeutics
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...